Home › Funds › MONTANOVA CAPITAL, LLC › RCUS

MONTANOVA CAPITAL, LLC position in RCUS

ARCUS BIOSCIENCES INC · Health Care

MONTANOVA CAPITAL, LLC reported holding 4,776,423 shares of RCUS (ARCUS BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$147.3M, representing 2.69% of its reported portfolio and ranking #10 among its reported holdings. MONTANOVA CAPITAL, LLC has disclosed RCUS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)4.78M sh
Reported value held$147.26M
Portfolio Weight2.69%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How MONTANOVA CAPITAL, LLC's RCUS position evolved

MONTANOVA CAPITAL, LLC first disclosed a stake in RCUS in Q3 2023 at 597,099 shares (US$10.7M). The position peaked in Q2 2026 at 4,776,423 shares, worth US$147.3M. Across 12 filings, MONTANOVA CAPITAL, LLC increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 4,776,423 shares valued at US$147.3M — a reduction of -254,570 shares quarter over quarter.. Notable position changes include a 60% increase in Q4 2023 (shares fell 1% over the following quarter), a 344% increase in Q1 2025 (shares rose 4% over the following quarter), a 44% increase in Q2 2025 (shares rose 67% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 597.10K $10.72M New
Q4 2023 957.30K $18.28M Add
Q1 2024 957.30K $18.07M Hold
Q2 2024 957.30K $14.58M Hold
Q3 2024 663.60K $10.15M Reduce
Q4 2024 576.16K $8.58M Reduce
Q1 2025 2.56M $20.10M Add
Q2 2025 3.69M $30.03M Add
Q3 2025 3.69M $50.17M Hold
Q4 2025 5.19M $123.65M Add
Q1 2026 5.03M $108.67M Reduce
Q2 2026 4.78M $147.26M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RCUS and 13F data

RCUS (ARCUS BIOSCIENCES INC) is a Health Care company. 46 other funds we track also report a position in RCUS — the largest reported positions include GILEAD SCIENCES, INC. (US$968.8M), Siren, L.L.C. (US$74.6M), SAMLYN CAPITAL, LLC (US$47.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RCUS

All RCUS fund holders →

FAQ

How long has MONTANOVA CAPITAL, LLC held RCUS?

MONTANOVA CAPITAL, LLC has disclosed RCUS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is MONTANOVA CAPITAL, LLC's current position in RCUS?

As of Q2 2026, MONTANOVA CAPITAL, LLC holds 4.78M shares of RCUS (ARCUS BIOSCIENCES INC), valued at $147.26M, representing 2.69% of its reported portfolio and ranking #10.

Has MONTANOVA CAPITAL, LLC been buying or selling RCUS?

In the latest 13F filing (Q2 2026), MONTANOVA CAPITAL, LLC reduced its position in RCUS. The position peaked in Q2 2026 at 4.78M shares.

Which other funds hold RCUS?

Other major institutional holders of RCUS include GILEAD SCIENCES, INC., Siren, L.L.C., SAMLYN CAPITAL, LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.